挑戰(zhàn):

• SARM1具顯著的動態(tài)構(gòu)象變化，體外難以穩(wěn)定并捕捉其激活態(tài)構(gòu)象；
• 目前的候選藥物分子主要為競爭性抑制劑，缺乏明確的抑制機(jī)制。

目標(biāo):

• 通過晶泰科技AI驅(qū)動的Cryo-EM圖像處理模塊，幫助加速解析抑制劑與SARM1的高分辨率電鏡結(jié)構(gòu)，為理性藥物設(shè)計(jì)提供新思路、新方向；
• 進(jìn)一步揭示該靶點(diǎn)的自抑制態(tài)與激活態(tài)的轉(zhuǎn)換機(jī)制，加深對靶點(diǎn)作用機(jī)理的理解。

結(jié)構(gòu)解析流程：

解析結(jié)果：

項(xiàng)目小結(jié)：

僅使用200kV電鏡，在8 周內(nèi)成功解析SARM1與抑制劑的2.8 ?結(jié)構(gòu)，這項(xiàng)開創(chuàng)性研究成果揭示了一種小分子抑制劑的競爭性抑制機(jī)制。高比例NMN/NAD+誘導(dǎo)激活SARM1，抑制劑在SARM1催化下與NAD+發(fā)生堿基交換反應(yīng)，生成抑制劑-ADPR這一新產(chǎn)物，該產(chǎn)物與SARM1結(jié)合并鎖定其處于激活態(tài)構(gòu)象，封鎖底物NAD+結(jié)合口袋，從而抑制SARM1的NAD+降解活性。該結(jié)果為證實(shí)SARM1的激活機(jī)制和堿基交換反應(yīng)提供了最直接的結(jié)構(gòu)證據(jù)。

數(shù)據(jù)計(jì)算過程中，通過使用 AI 驅(qū)動的圖像處理模塊實(shí)現(xiàn)了目標(biāo)顆粒的精確挑選，與經(jīng)典方法相比，在同等算力下，加速整體計(jì)算流程并實(shí)現(xiàn)更高的分辨率。

同時(shí)，首次從分子水平揭示了 SARM1 的激活機(jī)制，加深對其如何介導(dǎo)退行性疾病發(fā)生機(jī)理的理解。

The post 8周解析SARM1蛋白結(jié)構(gòu) appeared first on 晶泰科技 XtalPi.

Case Study: How XtalPi Used Diversity Library of 80K Compounds to Find Hits Targeting FGFR3 

Mutations in Fibroblast Growth Factor Receptor 3 (FGFR3) are linked to various cancers, making it a critical target for therapeutic intervention. But targeting specific FGFR members individually is very challenging due to their structural similarities. Currently only pan-inhibitors are approved by the FDA.

In an effort to selectively target FGFR3, XtalPi sought to identify novel scaffolds using our curated?high-throughput screening (HTS) diversity library.

Our Key Results:

• Discovery of 15 potent hit compounds, each exhibiting biochemical potency with IC₅₀ values below 10 μM.
• Identified three hit series which possessed novel scaffolds that are distinct from those of known FGFR3 inhibitors, providing new avenues for selectively targeting the protein.

The post Identifying Novel FGFR3 Inhibitors By XtalPi-Curated HTS Diversity Library appeared first on 晶泰科技 XtalPi.

Case Study: How the XtalPi Team Discovered Novel, Non-Covalent, Potent Hits Against GPX4 in 28 Days

GPX4 is a critical enzyme for cellular antioxidant defense, but is a highly challenging target. In this case study, we share the story of how we discovered three novel non-covalent hit compounds with biochemical IC₅₀?< 10μM in just 28 days.

• Using predictive AI models and physics-based computations, we probed key pharmacophores with high accuracy and throughput, even without reference compounds.
• 159 library compounds were proposed and 124 were successfully synthesized using our automation platform.

The post Hit Identification – Novel Hits for GPX4 appeared first on 晶泰科技 XtalPi.

Case Study: How the XtalPi Team Discovered a Selective, Novel Lead Series for Key Cancer Target SMARCA2

Loss-of-function mutations in SMARCA4 occur in various cancers, leading to an increased dependency on the structurally similar SMARCA2 for activity. This makes SMARCA2 an attractive therapeutic target due to its increased importance in cancer cell survival.

However, identifying novel small-molecule SMARCA2-selective inhibitors poses significant challenges. To address this, XtalPi leveraged its advanced AI-powered discovery platform and Cryo-EM technology, opening up new possibilities for targeted cancer treatments.

Our Key Results: 

• Discovered a novel lead series with high efficacy and 20-fold selectivity for SMARCA2 over SMARCA4 in biochemical assays, showcasing strong potential for further development.
• Identified a unique SMARCA2 binding pocket using Cryo-EM at 2.9 ? resolution, offering new insights for the design of selective inhibitors and advancing structure-based drug discovery.
• Achieved 100% library compound synthetic success rate by proprietary synthetic feasibility prediction models.

The post Lead Identification – Discovering Selective Inhibitors Against an Unreported Binding Pocket of SMARCA2 via a Rational Drug Design Approach appeared first on 晶泰科技 XtalPi.